Familial Amyloid Polyneuropathy Market
Key Highlights
- The familial amyloid polyneuropathy market is expected to grow significantly by 2036.
- The leading companies active in the familial amyloid polyneuropathy market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, BridgeBio Pharma, Intellia Therapeutics, Regeneron Pharmaceuticals, Purpose Pharma International, Accuredit Therapeutics, and YolTech Therapeutics.
DelveInsight's "Familial Amyloid Polyneuropathy Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Familial Amyloid Polyneuropathy, historical and forecasted epidemiology as well as the Familial Amyloid Polyneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Familial Amyloid Polyneuropathy market report provides current treatment practices, emerging drugs, Familial Amyloid Polyneuropathy market share of the individual therapies, current and forecasted Familial Amyloid Polyneuropathy market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Familial Amyloid Polyneuropathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Familial Amyloid Polyneuropathy market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2022-2036
Key Factors Driving the Familial Amyloid Polyneuropathy (FAP) Market
- Increasing Awareness and Diagnosis of Hereditary ATTR Amyloidosis: Improved awareness of familial amyloid polyneuropathy among healthcare professionals and patients is contributing to earlier disease recognition. Greater understanding of its multisystem manifestations, including peripheral neuropathy, autonomic dysfunction, and cardiac involvement, is supporting increased diagnosis and treatment initiation.
- Advancements in Genetic Testing and Diagnostic Technologies: The growing availability of genetic testing, including TTR gene sequencing, is facilitating the identification of pathogenic mutations associated with hereditary transthyretin amyloidosis. Improved diagnostic capabilities and increased screening of at-risk family members are supporting earlier detection and expanding the diagnosed patient population.
- Growing Adoption of Disease-Modifying Therapies: The availability of disease-modifying treatments, including transthyretin (TTR) stabilizers and gene-silencing therapies, is transforming FAP management. Therapies such as tafamidis, patisiran, vutrisiran, and eplontersen are supporting market growth by offering targeted treatment approaches that address disease progression rather than symptoms alone.
- Increasing Demand for RNA-Based Gene-Silencing Therapies: The development of RNA interference (RNAi) and antisense oligonucleotide (ASO) therapies is driving significant market expansion. These approaches reduce hepatic TTR production, thereby lowering the formation of amyloid deposits and slowing neurological deterioration, with improvements in neuropathy-related outcomes supporting broader treatment adoption.
- Rising Investments in Research and Development: Pharmaceutical companies are increasingly investing in the development of innovative therapies targeting ATTRv amyloidosis. Ongoing research into gene editing, next-generation RNA-based therapeutics, and improved drug delivery technologies is strengthening the pipeline and creating opportunities for future market expansion.
Familial Amyloid Polyneuropathy Disease Understanding and Treatment Algorithm
Familial Amyloid Polyneuropathy (FAP), also known as hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), is a rare, progressive, and potentially life-threatening autosomal dominant genetic disorder caused by mutations in the transthyretin (TTR) gene. These mutations result in the production of unstable transthyretin proteins that misfold and form amyloid fibrils, which progressively accumulate in peripheral nerves and various organs, including the heart, kidneys, and gastrointestinal tract. The disease primarily affects the peripheral nervous system, leading to progressive sensory, motor, and autonomic neuropathy. Common manifestations include numbness, tingling, pain, muscle weakness, impaired mobility, gastrointestinal disturbances, orthostatic hypotension, and cardiac complications. Symptoms typically develop during adulthood, although the age of onset and disease progression vary depending on the specific genetic mutation and geographic background. The progressive nature of FAP can significantly impair patients' quality of life, increase disability, and reduce life expectancy if left untreated.
Familial Amyloid Polyneuropathy Diagnosis
The diagnosis of Familial Amyloid Polyneuropathy involves a combination of clinical evaluation, genetic testing, neurological assessments, and laboratory investigations to confirm the presence of hereditary transthyretin amyloidosis and distinguish it from other forms of peripheral neuropathy. Initial assessment includes reviewing family history, evaluating neurological symptoms, and identifying signs of progressive sensory, motor, and autonomic dysfunction. Genetic testing, particularly DNA sequencing of the TTR gene, plays a central role in confirming pathogenic mutations associated with the disease. Additional diagnostic procedures include nerve conduction studies and electromyography to assess peripheral nerve damage, while tissue biopsy of affected sites, such as abdominal fat, skin, or salivary glands, may be performed to detect amyloid deposits using Congo red staining. Technetium-based cardiac scintigraphy, echocardiography, cardiac MRI, and blood or urine biomarker assessments may also be used to evaluate cardiac involvement and disease severity. Early and accurate diagnosis is essential for initiating disease-modifying treatment before irreversible neurological damage occurs.
Familial Amyloid Polyneuropathy Treatment
The treatment of Familial Amyloid Polyneuropathy focuses on reducing the production of abnormal transthyretin protein, preventing further amyloid deposition, managing disease symptoms, and slowing neurological deterioration. Disease-modifying therapies primarily include TTR gene-silencing agents, such as patisiran (ONPATTRO), vutrisiran (AMVUTTRA), and eplontersen (WAINUA), which reduce hepatic production of transthyretin through RNA interference or antisense oligonucleotide mechanisms. TTR stabilizers, including tafamidis (VYNDAQEL) and diflunisal, help prevent transthyretin tetramer dissociation and subsequent amyloid fibril formation. In selected patients, liver transplantation has historically been used to replace the primary source of abnormal transthyretin production, although its role has declined with the availability of targeted pharmacological therapies. Supportive management includes medications for neuropathic pain, gastrointestinal symptoms, orthostatic hypotension, and other autonomic complications, alongside physical therapy and nutritional support. The emergence of RNA-targeting therapies and other novel approaches has expanded the treatment landscape, offering opportunities to slow disease progression, preserve neurological function, and improve long-term patient outcomes.
Familial Amyloid Polyneuropathy Epidemiology
The Familial Amyloid Polyneuropathy epidemiology section provides insights about the historical and current Familial Amyloid Polyneuropathy patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Familial Amyloid Polyneuropathy market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Familial Amyloid Polyneuropathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.
Country Wise- Familial Amyloid Polyneuropathy Epidemiology
The epidemiology segment also provides the Familial Amyloid Polyneuropathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Familial Amyloid Polyneuropathy Drug Chapters
The drug chapter segment of the Familial Amyloid Polyneuropathy report encloses the detailed analysis of Familial Amyloid Polyneuropathy marketed drugs and late-stage (Phase-III and Phase-II) Familial Amyloid Polyneuropathy pipeline drugs. It also helps to understand the Familial Amyloid Polyneuropathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Familial Amyloid Polyneuropathy Marketed Drugs
Vutrisiran (AMVUTTRA): Alnylam Pharmaceuticals
Vutrisiran (AMVUTTRA) is a SC administered transthyretin-directed small interfering ribonucleic acid (siRNA) therapeutic (also called RNA interference, or RNAi therapeutic) being developed by Alnylam Pharmaceuticals, Inc. for the treatment of ATTR amyloidosis, including hATTR amyloidosis and wild-type ATTR (wtATTR) amyloidosis. Vutrisiran was approved in June 2022 in the USA for the treatment of the polyneuropathy of hATTR amyloidosis in adults and received a positive opinion in the EU in July 2022 for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. Vutrisiran is also under regulatory review for the treatment of the polyneuropathy of hATTR amyloidosis in adults in Japan. This article summarises the milestones in the development of vutrisiran leading to this first approval in hATTR amyloidosis.
Familial Amyloid Polyneuropathy Emerging Drugs
Nucresiran (ALN-TTRsc04): Alnylam Pharmaceuticals
Nucresiran is a next-generation small interfering RNA (siRNA)-based therapeutic being developed by Alnylam Pharmaceuticals for the treatment of hereditary transthyretin amyloidosis with polyneuropathy. The drug is designed to suppress the production of transthyretin (TTR) protein in the liver by targeting TTR messenger RNA (mRNA), thereby reducing the formation and accumulation of amyloid deposits in peripheral nerves and other affected tissues. Nucresiran is being evaluated in the Phase III TRITON-PN trial (NCT07223203), which assesses its efficacy and safety in patients with hATTR-PN, including improvements in neurological impairment, quality of life, nutritional status, disability, and gait speed. The investigational therapy is designed for twice-yearly subcutaneous administration, potentially offering a less frequent dosing schedule than existing TTR-silencing treatments. The Phase III study is ongoing and includes a comparison with vutrisiran.
Nexiguran Ziclumeran (Nex-z; NTLA-2001): Intellia Therapeutics / Regeneron Pharmaceuticals
Nexiguran ziclumeran is an investigational in vivo CRISPR/Cas9-based gene-editing therapy being developed by Intellia Therapeutics in collaboration with Regeneron Pharmaceuticals for hereditary transthyretin amyloidosis with polyneuropathy. The therapy uses lipid nanoparticle delivery to transport CRISPR/Cas9 gene-editing components to liver cells, where it is designed to permanently inactivate the TTR gene and prevent the production of transthyretin protein. Unlike conventional RNA interference and antisense oligonucleotide therapies that require repeated administration, nexiguran ziclumeran is being investigated as a potential one-time intravenous treatment capable of producing sustained TTR reduction. Its clinical development includes the Phase III MAGNITUDE-2 study (NCT06672237), which evaluates its efficacy and safety in patients with ATTRv-PN, with changes in modified Neuropathy Impairment Score and serum TTR levels among the key endpoints. Intellia announced completion of patient enrollment in November 2026, marking an important milestone in the program's development.
Recent Developments in the Familial Amyloid Polyneuropathy Market
- In March 2026, Intellia Therapeutics presentation, the Nex-Z ATTR program outlines a planned resumption of patient enrollment in the Phase III MAGNITUDE trial in ATTR-CM, resumption of patient enrollment in the Phase III MAGNITUDE-2 trial in ATTRv-PN, and expected completion of enrollment in MAGNITUDE-2 in the second half of 2026.
- In February 2026, according to the Q4 and Full Year 2025 financial results of Alnylam Pharmaceuticals, the company plans to launch Nucresiran, a next-generation RNA silencer for Transthyretin Amyloidosis, with a potential launch timeline of 2028 for polyneuropathy and 2030 for cardiomyopathy indications.
Familial Amyloid Polyneuropathy Market Outlook
The Familial Amyloid Polyneuropathy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Familial Amyloid Polyneuropathy market trends by analyzing the impact of current Familial Amyloid Polyneuropathy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Familial Amyloid Polyneuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Familial Amyloid Polyneuropathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Familial Amyloid Polyneuropathy market in 7MM is expected to witness a major change in the study period 2022-2036.
Key Findings
This section includes a glimpse of the Familial Amyloid Polyneuropathy market in 7MM.
The United States Market Outlook
This section provides the total Familial Amyloid Polyneuropathy market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Familial Amyloid Polyneuropathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Familial Amyloid Polyneuropathy market size and market size by therapies in Japan is also mentioned.
Familial Amyloid Polyneuropathy Drugs Uptake
This section focuses on the rate of uptake of the potential Familial Amyloid Polyneuropathy drugs recently launched in the Familial Amyloid Polyneuropathy market or expected to get launched in the market during the study period 2022-2036. The analysis covers Familial Amyloid Polyneuropathy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Familial Amyloid Polyneuropathy Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Familial Amyloid Polyneuropathy market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Familial Amyloid Polyneuropathy Pipeline Development Activities
The Familial Amyloid Polyneuropathy report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Familial Amyloid Polyneuropathy key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Familial Amyloid Polyneuropathy report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Familial Amyloid Polyneuropathy emerging therapies.
Reimbursement Scenario in Familial Amyloid Polyneuropathy
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Familial Amyloid Polyneuropathy market trends, we take KOLs and SMEs ' opinion working in the Familial Amyloid Polyneuropathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Familial Amyloid Polyneuropathy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Familial Amyloid Polyneuropathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Familial Amyloid Polyneuropathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Familial Amyloid Polyneuropathy epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Familial Amyloid Polyneuropathy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Familial Amyloid Polyneuropathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Familial Amyloid Polyneuropathy market
Report Highlights
- In the coming years, the Familial Amyloid Polyneuropathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Familial Amyloid Polyneuropathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Familial Amyloid Polyneuropathy. The launch of emerging therapies will significantly impact the Familial Amyloid Polyneuropathy market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Familial Amyloid Polyneuropathy
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Familial Amyloid Polyneuropathy Report Insights
- Familial Amyloid Polyneuropathy Patient Population
- Therapeutic Approaches
- Familial Amyloid Polyneuropathy Pipeline Analysis
- Familial Amyloid Polyneuropathy Market Size and Trends
- Familial Amyloid Polyneuropathy Market Opportunities
- Impact of upcoming Familial Amyloid Polyneuropathy Therapies
Familial Amyloid Polyneuropathy Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Familial Amyloid Polyneuropathy Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Familial Amyloid Polyneuropathy Report Assessment
- Current Treatment Practices
- Unmet Needs
- Familial Amyloid Polyneuropathy Pipeline Product Profiles
- Familial Amyloid Polyneuropathy Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Familial Amyloid Polyneuropathy drug class share (%) distribution in 2022 and how it would look like in 2036?
- What would be the Familial Amyloid Polyneuropathy total market size as well as market size by therapies across the 7MM during the forecast period (2022-2036)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Familial Amyloid Polyneuropathy market size during the forecast period (2022-2036)?
- At what CAGR, the Familial Amyloid Polyneuropathy market is expected to grow by 7MM during the forecast period (2022-2036)?
- What would be the Familial Amyloid Polyneuropathy market outlook across the 7MM during the forecast period (2022-2036)?
- What would be the Familial Amyloid Polyneuropathy market growth till 2036, and what will be the resultant market Size in the year 2036?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Familial Amyloid Polyneuropathy?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Familial Amyloid Polyneuropathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Familial Amyloid Polyneuropathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Amyloid Polyneuropathy?
- Out of all 7MM countries, which country would have the highest prevalent population of Familial Amyloid Polyneuropathy during the forecast period (2022-2036)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2022-2036)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Familial Amyloid Polyneuropathy treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Familial Amyloid Polyneuropathy in the USA, Europe, and Japan?
- What are the Familial Amyloid Polyneuropathy marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Familial Amyloid Polyneuropathy?
- How many therapies are in-development by each company for Familial Amyloid Polyneuropathy treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Familial Amyloid Polyneuropathy treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Familial Amyloid Polyneuropathy therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Familial Amyloid Polyneuropathy and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Familial Amyloid Polyneuropathy?
- What are the global historical and forecasted market of Familial Amyloid Polyneuropathy?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Familial Amyloid Polyneuropathy market
- To understand the future market competition in the Familial Amyloid Polyneuropathy market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Familial Amyloid Polyneuropathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Familial Amyloid Polyneuropathy market
- To understand the future market competition in the Familial Amyloid Polyneuropathy market


-pipeline.png&w=256&q=75)

